Phase I trial of apalutamide (Apa) with abiraterone acetate (AA) plus prednisone (P) and docetaxel (Doce) in patients with metastatic castration-resistant prostate cancer (mCRPC).

被引：0
|
作者：
Nauseef, Jones T. [1 ]
Christos, Paul J. [2 ]
Thomas, Charlene [3 ]
Nordquist, Luke T. [4 ]
Sternberg, Cora N. [5 ]
Beltran, Himisha [6 ]
Guervil, Sabrina [7 ]
Galletti, Giuseppe [8 ]
Giannakakou, Paraskevi [8 ]
Nanus, David M. [9 ]
Tagawa, Scott T. [10 ]
Molina, Ana M. [3 ]
机构：
[1] Weill Cornell Med Ctr, NewYork Presbyterian Hosp, New York, NY USA
[2] Weill Cornell Med Coll, Dept Biostat & Epidemiol, New York, NY USA
[3] Weill Cornell Med, New York, NY USA
[4] GU Res Network, Omaha, NE USA
[5] Weill Cornell Med, Englander Inst Precis Med, New York, NY USA
[6] Dana Farber Canc Inst, Boston, MA 02115 USA
[7] Weill Cornell Med Ctr, New York, NY USA
[8] Meyer Canc Ctr, Weill Cornell Med, New York, NY USA
[9] Sandra & Edward Meyer Canc Ctr, New York, NY USA
[10] Weill Cornell Med Coll, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期
关键词：
D O I：
10.1200/JCO.2021.39.6_suppl.140
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
140
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Phase II study of prednisone-dexamethasone switch in metastatic castration resistant prostate cancer (mCRPC) patients treated with abiraterone and prednisone (AA plus P)
    Lozano Mejorada, R.
    Romero Laorden, N.
    Jayaram, A.
    Lopez, F.
    Saez, M. I.
    Villatoro, R.
    Montesa, A.
    Moreno, I.
    Ruiz Vico, M.
    Garcia Ferron, M.
    Rogado, J.
    Cendon Florez, Y.
    Nombela Blanco, P.
    Rivera, L.
    Grau, G.
    Cruz Hernandez, J. J.
    Lorente Estelles, D.
    Attard, G.
    Castro Marcos, E.
    Olmos Hidalgo, D.
    ANNALS OF ONCOLOGY, 2017, 28
  • [22] Use of Prednisone With Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer
    Auchus, Richard J.
    Yu, Margaret K.
    Nguyen, Suzanne
    Mundle, Suneel D.
    ONCOLOGIST, 2014, 19 (12): : 1231 - 1240
  • [23] Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer
    A. W. Tolcher
    K. N. Chi
    N. D. Shore
    R. Pili
    A. Molina
    M. Acharya
    T. Kheoh
    J. J. Jiao
    M. Gonzalez
    A. Trinh
    C. Pankras
    N. Tran
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 305 - 313
  • [24] Analysis of two poor prognosis subgroups in ACIS evaluating apalutamide plus abiraterone acetate plus prednisone (APA plus AAP) versus placebo (PBO) plus AAP in metastatic castration-resistant prostate cancer (mCRPC).
    Saad, Fred
    Efstathiou, Eleni
    Attard, Gerhardt
    Flaig, Thomas W.
    Franke, Fabio
    Goodman, Oscar
    Oudard, Stephane
    Steuber, Thomas
    Suzuki, Hiroyoshi
    Pieczonka, Christopher Michael
    Parnis, Francis
    Wu, Daphne
    Yeruva, Kesav
    De Porre, Peter
    Brookman-May, Sabine Doris
    Li, Susan
    Li, Jinhui
    Mundle, Suneel
    McCarthy, Sharon Anne
    Rathkopf, Dana E.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [25] Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer
    Tolcher, A. W.
    Chi, K. N.
    Shore, N. D.
    Pili, R.
    Molina, A.
    Acharya, M.
    Kheoh, T.
    Jiao, J. J.
    Gonzalez, M.
    Trinh, A.
    Pankras, C.
    Tran, N.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (02) : 305 - 313
  • [26] Safety and clinical outcomes of abiraterone acetate (aa) after docetaxel (doc) in octogenarians with metastatic castration-resistant prostate cancer (mcrpc)
    Caffo, O.
    Maines, F.
    De Giorgi, U.
    Fratino, L.
    Lo Re, G.
    Zagonel, V.
    D'Angelo, A.
    Donini, M.
    Verderame, F.
    Ratta, R.
    Procopio, G.
    Campadelli, E.
    Massari, F.
    Gasparro, D.
    Ermacora, P.
    Messina, C.
    Giordano, M.
    Alesini, D.
    Conteduca, V.
    Veccia, A.
    Galligioni, E.
    ANNALS OF ONCOLOGY, 2015, 26 : 61 - 61
  • [27] Results of a multicenter phase I/II trial of abiraterone acetate plus BEZ235 in metastatic, castration-resistant prostate cancer (mCRPC)
    Siegel, Adam Phillip
    Bryce, Alan Haruo
    Lin, Amy M.
    Friedlander, Terence W.
    Hsieh, Andrew Caleb
    Hang, Evelyn
    Weinberg, Vivian K.
    Ryan, Charles J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [28] Phase 1/2 trial of cabazitaxel with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone acetate: Phase 2 results.
    Mateo, Joaquin
    Fizazi, Karim
    Pezaro, Carmel Jo
    Loriot, Yohann
    Mehra, Niven
    Albiges, Laurence
    Bianchini, Diletta
    Varga, Andrea
    Ryan, Charles J.
    Petrylak, Daniel Peter
    Shen, Liji
    Zhang, Jenny
    Attard, Gerhardt
    De Bono, Johann Sebastian
    Massard, Christophe
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [29] A phase II study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Einstein, David Johnson
    Choudhury, Atish Dipankar
    Saylor, Philip James
    Werner, Lillian
    Erlander, Mark G.
    Ridinger, Maya
    Bubley, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [30] A phase II study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Einstein, David Johnson
    Choudhury, Atish Dipankar
    Saylor, Philip James
    Patterson, Jesse Christopher
    Croucher, Peter
    Ridinger, Maya
    Erlander, Mark G.
    Yaffe, Michael B.
    Bubley, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
12345